Erel C Tamer, Senturk Levent M, Kaleli Semih
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Cerrahpasa School of Medicine, Istanbul University, Istanbul 81070, Turkey.
Postgrad Med J. 2006 Oct;82(972):658-62. doi: 10.1136/pgmj.2005.037184.
Tibolone is a relatively new drug for postmenopausal women, which is structurally related to 19-nortestosterone derivatives and exhibits weak oestrogenic, progestogenic and androgenic activities. The effect of tibolone on breast tissue is still obscure. In vitro studies have shown conflicting results regarding the effects of tibolone on breast cells. On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. However, the safety of tibolone with regard to breast tissue needs to be investigated further, especially through well-designed, large-scale, randomised-controlled trials.
替勃龙是一种用于绝经后女性的相对新药，其在结构上与19-去甲睾酮衍生物相关，并具有微弱的雌激素、孕激素和雄激素活性。替勃龙对乳腺组织的影响仍不明确。体外研究显示，关于替勃龙对乳腺细胞的影响存在相互矛盾的结果。另一方面，尽管流行病学研究表明接受替勃龙治疗的女性患乳腺癌的风险增加，但放射学研究获得的数据积累呈现出有前景的结果。然而，替勃龙在乳腺组织方面的安全性仍需进一步研究，尤其是通过精心设计的大规模随机对照试验。
